zanidatamab zovodotin (ZW49)

News alerts, weekly reports and conference planners

Company:

BeiGene, Zymeworks

Drug class:

Microtubule inhibitor, HER2-targeted antibody-drug conjugate

HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	ZW49 Sensitive: C2 – Inclusion Criteria ZW49 Sensitive : C2	ZW49 Sensitive: C2 – Inclusion Criteria ZW49 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ZW49 Sensitive: C3 – Early Trials ZW49 Sensitive : C3	ZW49 Sensitive: C3 – Early Trials ZW49 Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	ZW49 Sensitive: C3 – Early Trials ZW49 Sensitive : C3	ZW49 Sensitive: C3 – Early Trials ZW49 Sensitive : C3

Associations
(3)